Skip to main content
Top

Open Access 25-04-2024 | Ruxolitinib | Research

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Authors: Aleksander Chojecki, Danielle Boselli, Allison Dortilus, Issam Hamadeh, Stephanie Begley, Tommy Chen, Rupali Bose, Nikolai Podoltsev, Amer M. Zeidan, Nicole Baranda Balmaceda, Abdulraheem Yacoub, Jing Ai, Thomas Gregory Knight, Brittany Knick Ragon, Nilay Arvind Shah, Srinivasa Reddy Sanikommu, James Symanowski, Ruben Mesa, Michael Richard Grunwald

Published in: Annals of Hematology

Login to get access

Abstract

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin and/or hematocrit levels. Patients often have symptoms such as fatigue, pruritus, and painful splenomegaly, but are also at risk of thrombosis, both venous and arterial. Ruxolitinib, a selective Janus kinase inhibitor, is approved by the US Food and Drug Administration as second-line cytoreductive treatment after intolerance or inadequate response to hydroxyurea. Although ruxolitinib has been widely used in this setting, limited data exist in the literature on ruxolitinib treatment patterns and outcomes among patients with PV in routine clinical practice. We report a retrospective, observational, cohort study of patients treated for PV with ruxolitinib across three US centers (academic and regional practice) from December 2014-December 2019. The study included 69 patients, with a median follow-up duration of 3.7 years (95% CI, 2.9–4.4). Our data demonstrate very high rates of hematocrit control (88% of patients by three months and 89% by six months); few patients required dose adjustments or suspension. No arterial thromboses were observed; however, the follow-up duration does not allow for the generation of meaningful conclusions from this. Three patients had thrombotic events; one was in the setting of a second malignancy, one post-operative, and a third related to prolonged immobility. We also found that 28% of patients initiated ruxolitinib as a result of poorly controlled platelet counts, second only to hydroxyurea intolerance (46%) as a reason to start therapy. In clinical practice, ruxolitinib continues to be effective in controlling hematocrit levels after three and six months of treatment in patients and is associated with low thrombotic risk.
Literature
2.
10.
go back to reference Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V et al (2022) Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer 128(13):2441–2448. https://doi.org/10.1002/cncr.34195CrossRefPubMed Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V et al (2022) Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer 128(13):2441–2448. https://​doi.​org/​10.​1002/​cncr.​34195CrossRefPubMed
12.
go back to reference Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88–99. https://doi.org/10.1016/s1470-2045(16)30558-7CrossRefPubMed Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88–99. https://​doi.​org/​10.​1016/​s1470-2045(16)30558-7CrossRefPubMed
13.
go back to reference Pepe S, Rossi E, Trawinska M, Tatarelli C, Di Veroli A, Maurillo L, Romano A, Crescenzi SL, di Toritto TC, Tafuri A et al (2022) Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. Ann Hematol 101(6):1275–1282. https://doi.org/10.1007/s00277-022-04815-wCrossRefPubMed Pepe S, Rossi E, Trawinska M, Tatarelli C, Di Veroli A, Maurillo L, Romano A, Crescenzi SL, di Toritto TC, Tafuri A et al (2022) Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. Ann Hematol 101(6):1275–1282. https://​doi.​org/​10.​1007/​s00277-022-04815-wCrossRefPubMed
Metadata
Title
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Authors
Aleksander Chojecki
Danielle Boselli
Allison Dortilus
Issam Hamadeh
Stephanie Begley
Tommy Chen
Rupali Bose
Nikolai Podoltsev
Amer M. Zeidan
Nicole Baranda Balmaceda
Abdulraheem Yacoub
Jing Ai
Thomas Gregory Knight
Brittany Knick Ragon
Nilay Arvind Shah
Srinivasa Reddy Sanikommu
James Symanowski
Ruben Mesa
Michael Richard Grunwald
Publication date
25-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05735-7
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare